Renal anemia is a serious and common complication of chronic kidney disease (CKD). An in-depth examination of the drivers and obstacles facing nephrologists provides greater insights on product…
Epilepsy is a heterogeneous condition requiring individualized treatment, based largely on a patient’s seizure syndrome and seizure type. Epilepsy patients also differ widely in their responses…
The most common problems associated with treating dyslipidemia are identifying patients who need to be treated, determining how aggressively they should be treated, and then encouraging them to…
Lennox-Gastaut syndrome (LGS) is a severe, pediatric-onset epilepsy syndrome characterized by developmental delay or regression, multiple seizure types, and electroencephalographic abnormalities…
Faced with the financial pressures of reimbursing a robust pipeline of new and expensive cancer therapies, U.S. managed care organizations (MCOs) are increasing their focus on managing the…
Chronic pain is a broad term encompassing many nociceptive, inflammatory, and neuropathic pain subtypes that can result from complex mechanisms affecting multiple pathophysiological pathways in the…
Introduction Alzheimer’s disease is a chronic disease than affects several million Brazilian and Mexican patients. Physicians have a small number of molecules available for the treatment of…
Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. The continued…
The RSV therapy market is characterized by a large and growing population of people at risk of infection every year. At greatest risk are infants and the elderly. No interventions are approved for…
Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug…
Abstract: The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…
The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the…
The tumor necrosis factor alpha (TNF-a) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. Meeting…
The United States has seen a dramatic rise in the prevalence of chronic kidney disease (CKD) and its sequelae—namely, diabetes and hypertension. Patients with CKD are typically co-managed by many…
The U.S. asthma therapy market has long been dominated by several effective and well-established treatments, including inhaled and oral therapies, but following the recent approval of two biologics…
